Perspectives on Sustainability in the Pharmaceutical Industry

Around the world, pharmaceutical companies and their industrial and academic partners stand firm in their commitment to the application of green chemistry principles, tools, and metrics. However, new challenges continue to emerge as the industry seeks to compress development timelines and extend portfolios to newer and more complex modalities. In this work, we share perspectives from across the industry on establishing science-based targets and building laboratory culture that empowers sustainability-forward process development decisions. Effective direction of development decisions requires selecting appropriate metrics for the stage and scope of the process, and we explore solutions and current challenges to addressing this problem, including the extension of sustainability concepts beyond small molecules and into therapeutic peptides, oligonucleotides, and biologics.

Authors

Institutions

Publication Details

Journal
Organic Process Research & Development
Published
2026-04-27
DOI
https://doi.org/10.1021/acs.oprd.5c00454
Primary Topic
Chemistry and Chemical Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perspectives on Sustainability in the Pharmaceutical Industry

Michael E. Kopach, Martin D. Eastgate, Bettina Bommarius, Harrison B. Rose et al.
Organic Process Research & Development
Chemistry and Chemical Engineering
article

Perspectives on Sustainability in the Pharmaceutical Industry

Michael E. Kopach, Martin D. Eastgate, Bettina Bommarius, Harrison B. Rose, Moiz Diwan, Huey Shann Sue, Nima Yazdanpanah
article en

Abstract

Around the world, pharmaceutical companies and their industrial and academic partners stand firm in their commitment to the application of green chemistry principles, tools, and metrics. However, new challenges continue to emerge as the industry seeks to compress development timelines and extend portfolios to newer and more complex modalities. In this work, we share perspectives from across the industry on establishing science-based targets and building laboratory culture that empowers sustainability-forward process development decisions. Effective direction of development decisions requires selecting appropriate metrics for the stage and scope of the process, and we explore solutions and current challenges to addressing this problem, including the extension of sustainability concepts beyond small molecules and into therapeutic peptides, oligonucleotides, and biologics.

Organic Process Research & Development
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Georgia Institute of Technology (US), Eli Lilly (United States) (US), AbbVie (United States) (US), Bristol-Myers Squibb (United States) (US), Université Bourgogne Franche-Comté (FR), Short and Associates (United States) (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 7%
Chemistry and Chemical Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.